Ontology highlight
ABSTRACT:
SUBMITTER: Ribas A
PROVIDER: S-EPMC6719557 | biostudies-literature | 2018 Oct
REPOSITORIES: biostudies-literature
Ribas Antoni A Medina Theresa T Kummar Shivaani S Amin Asim A Kalbasi Anusha A Drabick Joseph J JJ Barve Minal M Daniels Gregory A GA Wong Deborah J DJ Schmidt Emmett V EV Candia Albert F AF Coffman Robert L RL Leung Abraham C F ACF Janssen Robert S RS
Cancer discovery 20180828 10
PD-1 inhibitors are approved for treating advanced melanoma, but resistance has been observed. This phase Ib trial evaluated intratumoral SD-101, a synthetic CpG oligonucleotide that stimulates Toll-like receptor 9 (TLR9), in combination with pembrolizumab in patients with unresectable or metastatic malignant melanoma. The most common adverse events related to SD-101 were injection-site reactions and transient, mild-to-moderate "flu-like" symptoms. Among the 9 patients naïve to anti-PD-1 therapy ...[more]